CA3013589A1 - Synthesis and composition of rapafucin libraries - Google Patents

Synthesis and composition of rapafucin libraries Download PDF

Info

Publication number
CA3013589A1
CA3013589A1 CA3013589A CA3013589A CA3013589A1 CA 3013589 A1 CA3013589 A1 CA 3013589A1 CA 3013589 A CA3013589 A CA 3013589A CA 3013589 A CA3013589 A CA 3013589A CA 3013589 A1 CA3013589 A1 CA 3013589A1
Authority
CA
Canada
Prior art keywords
substituted
unsubstituted
alkyl
alkenyl
alkynyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA3013589A
Other languages
English (en)
French (fr)
Inventor
Jun Liu
Jingxin Wang
Zufeng Guo
Sam Hong
Wukun LIU
Hanjing Peng
Manisha Das
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johns Hopkins University
Original Assignee
Johns Hopkins University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johns Hopkins University filed Critical Johns Hopkins University
Publication of CA3013589A1 publication Critical patent/CA3013589A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
    • C07K1/047—Simultaneous synthesis of different peptide species; Peptide libraries
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • C07K17/08—Peptides being immobilised on, or in, an organic carrier the carrier being a synthetic polymer
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2570/00—Omics, e.g. proteomics, glycomics or lipidomics; Methods of analysis focusing on the entire complement of classes of biological molecules or subsets thereof, i.e. focusing on proteomes, glycomes or lipidomes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
CA3013589A 2016-02-04 2017-02-03 Synthesis and composition of rapafucin libraries Abandoned CA3013589A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662291437P 2016-02-04 2016-02-04
US62/291,437 2016-02-04
PCT/US2017/016481 WO2017136708A1 (en) 2016-02-04 2017-02-03 Synthesis and composition of rapafucin libraries

Publications (1)

Publication Number Publication Date
CA3013589A1 true CA3013589A1 (en) 2017-08-10

Family

ID=59501078

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3013589A Abandoned CA3013589A1 (en) 2016-02-04 2017-02-03 Synthesis and composition of rapafucin libraries

Country Status (8)

Country Link
US (1) US10662220B2 (enExample)
EP (1) EP3411413A4 (enExample)
JP (2) JP6891183B2 (enExample)
CN (1) CN108713028B (enExample)
AU (1) AU2017214550B2 (enExample)
CA (1) CA3013589A1 (enExample)
MX (1) MX2018009405A (enExample)
WO (1) WO2017136708A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI852183B (zh) 2011-12-28 2024-08-11 日商中外製藥股份有限公司 胜肽化合物之環化方法
US10815489B2 (en) 2015-03-13 2020-10-27 Chugai Seiyaku Kabushiki Kaisha Modified aminoacyl-tRNA synthetase and use thereof
US11066416B2 (en) 2016-02-04 2021-07-20 The Johns Hopkins University Rapafucin derivative compounds and methods of use thereof
CN108697729B (zh) 2016-02-04 2023-05-09 约翰霍普金斯大学 新型GLUT抑制剂rapaglutin及其用途
WO2017136708A1 (en) * 2016-02-04 2017-08-10 The Johns Hopkins University Synthesis and composition of rapafucin libraries
AU2017214557B2 (en) * 2016-02-04 2022-05-19 The Johns Hopkins University Rapadocins, inhibitors of equilibrative nucleoside transporter 1 and uses thereof
US12391971B2 (en) 2017-01-31 2025-08-19 Chugai Seiyaku Kabushiki Kaisha Method for synthesizing peptides in cell-free translation system
EP3636807A4 (en) * 2017-06-09 2021-07-28 Chugai Seiyaku Kabushiki Kaisha CYCLIC PEPTIDE COMPOUND WITH HIGH MEMBRANE PERMEABILITY AND LIBRARY WITH IT
US12594275B2 (en) 2019-02-07 2026-04-07 The Regents Of The University Of California Immunophilin binding agents and uses thereof
KR102994657B1 (ko) * 2019-03-15 2026-07-22 추가이 세이야쿠 가부시키가이샤 방향족 아미노산 유도체의 제조 방법
WO2021067405A1 (en) * 2019-10-01 2021-04-08 The Johns Hopkins University Neuroprotective compounds and methods of use thereof
TW202126323A (zh) * 2019-10-01 2021-07-16 約翰斯赫普金斯大學 雷帕弗辛（Ｒａｐａｆｕｃｉｎ）衍生化合物及其使用方法
WO2021071931A1 (en) 2019-10-07 2021-04-15 The Johns Hopkins University Three-dimentional surface for protein and small molecule microarrays
CN120271673A (zh) * 2024-01-08 2025-07-08 重庆医科大学 一种化合物、包含其的药物组合物及其用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5798355A (en) * 1995-06-07 1998-08-25 Gpi Nil Holdings, Inc. Inhibitors of rotamase enzyme activity
US5527907A (en) 1993-11-19 1996-06-18 Abbott Laboratories Macrolide immunomodulators
US7056935B2 (en) 1995-06-07 2006-06-06 Gpi Nil Holdings, Inc. Rotamase enzyme activity inhibitors
CN1187127A (zh) * 1995-06-07 1998-07-08 吉尔福特药品有限公司 旋转异构酶活性抑制剂
US5696135A (en) 1995-06-07 1997-12-09 Gpi Nil Holdings, Inc. Inhibitors of rotamase enzyme activity effective at stimulating neuronal growth
JP2002503667A (ja) * 1998-02-13 2002-02-05 プレジデント・アンド・フェローズ・オブ・ハーバード・カレッジ 新規な二量体化剤、その製造および使用
US6984635B1 (en) 1998-02-13 2006-01-10 Board Of Trustees Of The Leland Stanford Jr. University Dimerizing agents, their production and use
GB0417852D0 (en) * 2004-08-11 2004-09-15 Biotica Tech Ltd Production of polyketides and other natural products
US20080306098A1 (en) * 2006-11-06 2008-12-11 Mutz Mitchell W Pharmacokinetics of protease inhibitors and other drugs
WO2010004304A1 (en) * 2008-06-17 2010-01-14 Biotica Technology Limited Novel compounds and methods for their production
AU2011336727B2 (en) * 2010-11-30 2016-11-03 The Johns Hopkins University Hybrid cyclic libraries and screens thereof
EP2607352A1 (en) 2011-12-22 2013-06-26 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Pipecolate-diketoamides for treatment of psychiatric disorders
US10167259B2 (en) * 2013-06-14 2019-01-01 The Board Of Regents Of The University Of Texas System Allosteric inhibitors of proteasome and methods of use thereof
WO2017136708A1 (en) * 2016-02-04 2017-08-10 The Johns Hopkins University Synthesis and composition of rapafucin libraries

Also Published As

Publication number Publication date
EP3411413A1 (en) 2018-12-12
JP2019510738A (ja) 2019-04-18
JP7158532B2 (ja) 2022-10-21
JP6891183B2 (ja) 2021-06-18
CN108713028A (zh) 2018-10-26
US20190092808A1 (en) 2019-03-28
WO2017136708A1 (en) 2017-08-10
JP2021138726A (ja) 2021-09-16
EP3411413A4 (en) 2019-09-18
US10662220B2 (en) 2020-05-26
AU2017214550B2 (en) 2024-03-07
MX2018009405A (es) 2018-11-09
CN108713028B (zh) 2021-12-28
AU2017214550A1 (en) 2018-08-16

Similar Documents

Publication Publication Date Title
AU2017214550B2 (en) Synthesis and composition of Rapafucin libraries
US12565518B2 (en) Hybrid cyclic libraries and screens thereof
Seebach et al. γ2‐, γ3‐, and γ2, 3, 4‐Amino acids, coupling to γ‐hexapeptides: CD spectra, NMR solution and X‐ray crystal structures of γ‐peptides
US20220298219A1 (en) Cyclic peptide analogs of melanocortin and amanitin and methods of making such
Rivera et al. A multicomponent conjugation strategy to unique N‐steroidal peptides: first evidence of the steroidal nucleus as a β‐turn inducer in acyclic peptides
Chakraborty et al. Design and Synthesis of a rapamycin-based high affinity binding FKBP12 ligand
Goncalves et al. On-resin cyclization of peptide ligands of the vascular endothelial growth factor receptor 1 by copper (I)-catalyzed 1, 3-dipolar azide–alkyne cycloaddition
Hymel et al. Design and synthesis of a new orthogonally protected glutamic acid analog and its use in the preparation of high affinity polo-like kinase 1 polo-box domain–binding peptide macrocycles
Atkinson et al. Development of small cyclic peptides targeting the CK2α/β interface
Derrer et al. Synthesis and conformational analysis of a type VIb β-turn mimetic based on an eight-membered lactam
Qiu et al. Unified flexible total synthesis of chlorofusin and artificial Click mimics as antagonists against p53–HDM2 interactions
Koba et al. Synthesis of chiral five‐membered carbocyclic ring amino acids with an acetal moiety and helical conformations of its homo‐chiral homopeptides
Ledwoń et al. Synthetic Strategies to Prepare Bioactive Lysine and Peptide Conjugates With Triazolium Derivatives
Scherkenbeck et al. Segment Solid‐Phase Total Synthesis of the Anthelmintic Cyclooctadepsipeptides PF1022A and Emodepside
Danieli et al. Synthesis and Conformational Analysis of Constrained β‐Turn Mimetics Incorporating a Bicyclic Turn Inducer by Use of the Petasis Three‐Component Reaction on Solid Phase
Voll Design, synthesis and biological evaluation of novel FKBP51 ligands
Xia et al. Solid phase synthesis of marine cyclopeptide phakellistatin 13
Boys Tyrosine derivatives and their anti-cancer applications
Purder et al. Picomolar FKBP inhibitors enabled by a single water-displacing methyl group in bicyclic [4.3. 1] aza-amides
Hewitt Utilization of the β-Lactum Core Towards the Preparation of Chiral Ring-Fused Lactams and Preparation and Application of Synthetic Peptide Libraries Toward the Discovery and Understanding of Membrane-Permeable Macrocycles
Fink I.~ Design, synthesis, and evaluation of a rigidly constrained peptidomimetic as a potential type I beta-turn. II.~ Development of novel estrogen receptor ligands with unique endocrine profiles. III.~ Design, synthesis and biological evaluation of potential aspartic protease inhibitors based on the diaziridine and diazirine isostere
Bakas I. Synthesis and Bioactivity of Novel Proteasome Inhibiting Syrbactins and II. Peptide Assembly by Ligation of Hydroxyl Amino Acids and Mildly Activated Esters
Rock Jr Caged polypeptides for the rapid triggering of protein conformational change
Akula Expanding the Spiroligomers Toolbox as Protein-Protein Interaction Inhibitors
Ross Peptidomimetic foldamers of β-secondary structural elements

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20230503